44 related articles for article (PubMed ID: 12374700)
21. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
23. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
24. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
25. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
26. Herceptin.
Shepard HM; Jin P; Slamon DJ; Pirot Z; Maneval DC
Handb Exp Pharmacol; 2008; (181):183-219. PubMed ID: 18071947
[TBL] [Abstract][Full Text] [Related]
27. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.
Lane HA; Motoyama AB; Beuvink I; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S21-2. PubMed ID: 11521716
[TBL] [Abstract][Full Text] [Related]
28. Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy.
Yanagawa T; Funasaka T; Tsutsumi S; Watanabe H; Raz A
Endocr Relat Cancer; 2004 Dec; 11(4):749-59. PubMed ID: 15613449
[TBL] [Abstract][Full Text] [Related]
29. The basic biology of HER2.
Rubin I; Yarden Y
Ann Oncol; 2001; 12 Suppl 1():S3-8. PubMed ID: 11521719
[TBL] [Abstract][Full Text] [Related]
30. The role of HER2 in angiogenesis.
Kumar R; Yarmand-Bagheri R
Semin Oncol; 2001 Oct; 28(5 Suppl 16):27-32. PubMed ID: 11706393
[TBL] [Abstract][Full Text] [Related]
31. Molecular approach to breast cancer treatment.
Yarden Y; Baselga J; Miles D
Semin Oncol; 2004 Oct; 31(5 Suppl 10):6-13. PubMed ID: 15490369
[TBL] [Abstract][Full Text] [Related]
32. HER-2 Positive Breast Cancer - a Mini-Review.
Asif HM; Sultana S; Ahmed S; Akhtar N; Tariq M
Asian Pac J Cancer Prev; 2016; 17(4):1609-15. PubMed ID: 27221828
[TBL] [Abstract][Full Text] [Related]
33. The role of autocrine motility factor in tumor and tumor microenvironment.
Funasaka T; Raz A
Cancer Metastasis Rev; 2007 Dec; 26(3-4):725-35. PubMed ID: 17828376
[TBL] [Abstract][Full Text] [Related]
34. [Possibility that AMF will serve as a target molecule for the diagnosis and treatment of a metastatic neoplasm].
Haga A
Yakugaku Zasshi; 2005 Feb; 125(2):169-75. PubMed ID: 15684571
[TBL] [Abstract][Full Text] [Related]
35. Autocrine motility factor and its receptor expression in musculoskeletal tumors.
Nakajima K; Raz A
J Bone Oncol; 2020 Oct; 24():100318. PubMed ID: 33101887
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor family and chemosensitization.
Mendelsohn J; Fan Z
J Natl Cancer Inst; 1997 Mar; 89(5):341-3. PubMed ID: 9060954
[No Abstract] [Full Text] [Related]
37. Antibody-based imaging of HER-2: moving into the clinic.
Wang RE; Zhang Y; Tian L; Cai W; Cai J
Curr Mol Med; 2013 Dec; 13(10):1523-37. PubMed ID: 24206138
[TBL] [Abstract][Full Text] [Related]
38. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
Talukder AH; Bagheri-Yarmand R; Williams RR; Ragoussis J; Kumar R; Raz A
Clin Cancer Res; 2002 Oct; 8(10):3285-9. PubMed ID: 12374700
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
